FINWIRES · TerminalLIVE
FINWIRES

BioNTech Shares Fall After Ending Phase 2 Colorectal Cancer Trial

By

BioNTech (BNTX) shares fell 9% in early Friday trading after the company said it has decided to terminate a phase 2 trial evaluating autogene cevumeran as an adjuvant monotherapy in patients with high-risk stage II or stage III colorectal cancer.

The trial's independent safety board recommended discontinuing treatment and ending the trial, saying further continuation was unlikely to change the efficacy outcome, according to the company.

A separate phase 2 trial evaluating autogene cevumeran in combination with checkpoint inhibition and chemotherapy for adjuvant pancreatic ductal adenocarcinoma is not affected and will continue as planned, the company said.

Price: $101.50, Change: $-9.90, Percent Change: -8.89%

What else is happening in Wire?

Wire

Update: PagerDuty Q2 Adjusted Earnings, Revenue Rise; Company Plans 15% Workforce Cut

(Updates with job cuts in the penultimate paragraph.)PagerDuty (PD) reported Thursday Q2 adjusted earnings of $0.32 per diluted share, up from $0.30 a year earlier.Analysts polled by FactSet expected $0.31.Revenue for the quarter ended July 31 rose to $124.4 million from $123.4 million a year earlier.Analysts projected $123.3 million.The company expects Q3 adjusted EPS of $0.34 to $0.36 on revenue of $123 million to $125 million. Analysts project EPS of $0.34 on revenue of $124.4 million.PagerDuty expects 2027 adjusted EPS of $1.33 to $1.37 on revenue of $491.5 million to $496.5 million. Analysts project EPS of $1.32 on revenue of $494.2 million.In a regulatory filing, the company said it plans to cut 15% of its workforce as part of a restructuring and record non-recurring charges of $5.5 million to $7.5 million related to the move.PagerDuty shares fell 2.4% in after-hours trading.

$PD
Wire

Affirm Fiscal Q4 Earnings, Revenue Rise; Shares Gain After-Hours

Affirm Holdings (AFRM) reported fiscal Q4 net income late Thursday of $4.62 per diluted share, up from $0.20 a year earlierAnalysts polled by FactSet expected $0.35, if comparable.Revenue for the quarter ended June 30 was $1.17 billion, up from $876.4 million a year earlier.Analysts expected $1.11 billion.For fiscal Q1, the company expects revenue of $1.19 billion to $1.22 billion.Analysts are looking for $1.16 billion.Shares rose over 6% in after-hours activity.

$AFRM
Wire

Elastic Q1 Adjusted Earnings, Revenue Rise; Shares Surge After Hours

Elastic (ESTC) reported fiscal Q1 non-GAAP earnings late Thursday of $0.70 per diluted share, up from $0.60 a year earlier.Analysts polled by FactSet expected $0.58.Revenue in the three months ended July 31 rose to $478.1 million from $415.3 million a year earlier.Analysts projected $469.7 million.The company expects fiscal Q2 non-GAAP EPS of $0.80 to $0.82 on revenue of $486 million to $487 million.Analysts project EPS of $0.79 on revenue of $483.5 million.Elastic boosted fiscal 2027 guidance to non-GAAP EPS of $3.29 to $3.37 on revenue of $1.998 billion to $2.01 billion, up from the prior forecast of EPS of $3.21 to $3.29 on revenue of $1.985 billion to $2 billion.Analysts expect EPS of $3.24 on revenue of $1.996 billion.Elastic shares jumped 22% in after-hours trading.

$ESTC